Reported about 1 year ago
Eli Lilly is aiming to enter the multibillion-dollar non-alcoholic steatohepatitis (NASH) market with its drug tirzepatide, already a success in the diabetes and weight loss sectors. The rise in NASH cases, lack of existing treatments, and positive trial results make this a promising move. Despite competition in the NASH arena, analysts predict substantial growth for Eli Lilly. Considering strong revenue from current products and a robust pipeline, investing in Eli Lilly appears favorable.
Source: YAHOO